1819 related articles for article (PubMed ID: 25382096)
41. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
[TBL] [Abstract][Full Text] [Related]
43. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.
Anderson JE; Thieu VT; Boye KS; Hietpas RT; Garcia-Perez LE
Postgrad Med; 2016 Nov; 128(8):810-821. PubMed ID: 27488824
[TBL] [Abstract][Full Text] [Related]
44. Dulaglutide for the treatment of type 2 diabetes.
Amblee A
Drugs Today (Barc); 2014 Apr; 50(4):277-89. PubMed ID: 24918645
[TBL] [Abstract][Full Text] [Related]
45. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
47. Dulaglutide: A Review in Type 2 Diabetes.
Burness CB; Scott LJ
BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
[TBL] [Abstract][Full Text] [Related]
48. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
49. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
[TBL] [Abstract][Full Text] [Related]
50. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
[TBL] [Abstract][Full Text] [Related]
51. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
[TBL] [Abstract][Full Text] [Related]
52. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
53. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
[TBL] [Abstract][Full Text] [Related]
54. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
Wroge J; Williams NT
Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946
[TBL] [Abstract][Full Text] [Related]
55. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
56. An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
Brunton SA
J Fam Pract; 2018 Jun; 67(6 suppl):S3-S7. PubMed ID: 29912995
[TBL] [Abstract][Full Text] [Related]
57. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
58. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
[TBL] [Abstract][Full Text] [Related]
59. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
[TBL] [Abstract][Full Text] [Related]
60. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
Lorenz M; Evers A; Wagner M
Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
